4.8 Article

Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor

期刊

ONCOGENE
卷 28, 期 33, 页码 2959-2968

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2009.156

关键词

ubiquitin; ubiquitin E3 ligase; cancer; in situ hybridization; tissue microarrays

资金

  1. AIRC (Associazione Italiana per la Ricerca sul Cancro)
  2. AIRC and MIUR
  3. European Community (VI Framework)
  4. Ferrari Foundation
  5. Monzino Foundation
  6. CARIPLO Foundation
  7. G Vollaro Foundation

向作者/读者索取更多资源

Protein ubiquitination is critical for many cellular processes, through its ability to regulate protein degradation and various signaling mechanisms. In the ubiquitin (Ub) system, substrate specificity is achieved through the E3 family of Ub ligases. Because alterations of the ubiquitination machinery have been reported in human cancers, the selective interference with Ub ligases might represent a powerful therapeutic tool. Here, we report the first wide survey of misregulation of Ub ligases in cancer. We analysed 82 Ub ligases in nine types of cancer by in situ hybridization on tissue microarrays. We found 27 instances in which an Ub ligase was altered in a given type of tumor, when compared with normal tissues: 21 cases of overexpression and 6 cases of underexpression. We further analysed selected Ub ligases in large cohorts of breast and non-small-cell lung carcinomas. In five, of six, of these extended analyses (HUWE1, CCNB1IP1, SIAH1 and SIAH2 in breast cancer and CCNB1IP1 in lung cancer), we found that the levels of Ub ligases correlated significantly with relevant prognostic factors, and with clinical outcome. Our findings show that the alteration of Ub ligases is a frequent event in cancer and identify candidate targets for molecular therapies. Oncogene (2009) 28, 2959-2968; doi:10.1038/onc.2009.156; published online 22 June 2009

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC

Mari Mino-Kenudson, Nolwenn Le Stang, Jillian B. Daigneault, Andrew G. Nicholson, Wendy A. Cooper, Anja C. Roden, Andre L. Moreira, Erik Thunnissen, Mauro Papotti, Giuseppe Pelosi, Noriko Motoi, Claudia Poleri, Elisabeth Brambilla, Mary Redman, Deepali Jain, Sanja Dacic, Yasushi Yatabe, Ming Sound Tsao, Fernando Lopez-Rios, Johan Botling, Gang Chen, Teh-Ying Chou, Fred R. Hirsch, Mary Beth Beasley, Alain Borczuk, Lukas Bubendorf, Jin-Haeng Chung, David Hwang, Dongmei Lin, John Longshore, Masayuki Noguchi, Natasha Rekhtman, Lynette Sholl, William Travis, Akihiko Yoshida, Murry W. Wynes, Ignacio I. Wistuba, Keith M. Kerr, Sylvie Lantuejoul

Summary: The survey reveals heterogeneity in PD-L1 immunohistochemistry testing across regions and laboratories, highlighting the need for additional quality assurance measures, formal training, and standardized reporting.

JOURNAL OF THORACIC ONCOLOGY (2021)

Article Oncology

Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

P. Hofman, M. Ilie, E. Chamorey, P. Brest, R. Schiappa, V Nakache, M. Antoine, M. Barberis, H. Begueret, F. Bibeau, C. Bonnetaud, P. Bostroem, P. Brousset, L. Bubendorf, L. Carvalho, G. Cathomas, A. Cazes, L. Chalabreysse, M-P Chenard, M-C Copin, J-F Cote, D. Damotte, L. de Leval, P. Delongova, V. Thomas de Montpreville, A. de Muret, A. Dema, W. Dietmaier, M. Evert, A. Fabre, F. Forest, A. Foulet, S. Garcia, M. Garcia-Martos, L. Gibault, G. Gorkiewicz, D. Jonigk, J. Gosney, A. Hofman, I Kern, K. Kerr, M. Kossai, M. Kriegsmann, S. Lassalle, E. Long-Mira, A. Lupo, A. Mamilos, R. Matej, J. Meilleroux, C. Ortiz-Villalon, L. Panico, A. Panizo, M. Papotti, P. Pauwels, G. Pelosi, F. Penault-Llorca, O. Pop, N. Pote, S. R. Y. Cajal, J-C Sabourin, I Salmon, M. Sajin, S. Savic-Prince, H-U Schildhaus, P. Schirmacher, I Serre, E. Shaw, D. Sizaret, A. Stenzinger, J. Stojsic, E. Thunnissen, W. Timens, G. Troncone, C. Werlein, H. Wolff, J-P Berthet, J. Benzaquen, C-H Marquette, V Hofman, F. Calabrese

Summary: This study evaluated the impact of the COVID-19 outbreak on pathology laboratories in Europe, finding a significant decrease in workload in clinical and molecular pathology, a high proportion of employees working remotely, and the adoption of virtual meetings for training in most laboratories. Improved harmonization of biosafety procedures is needed.

ESMO OPEN (2021)

Article Oncology

Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer

Nuria Chic, Stephen J. Luen, Paolo Nuciforo, Roberto Salgado, Debora Fumagalli, Florentine Hilbers, Yingbo Wang, Evandro de Azambuja, Istvan Lang, Serena Di Cosimo, Cristina Saura, Jens Huober, Aleix Prat, Sherene Loi

Summary: The CelTIL score has been identified as a promising biomarker in early-stage HER2-positive breast cancer, showing potential to guide the escalation or deescalation of systemic therapy.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Letter Oncology

SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas

Jasna Metovic, Fabrizio Bianchi, Marco Barella, Mauro Papotti, Giuseppe Pelosi

JOURNAL OF THORACIC ONCOLOGY (2021)

Article Oncology

ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma

Helena Verdaguer, Tamara Sauri, Daniel Alejandro Acosta, Magdalena Guardiola, Alexandre Sierra, Jorge Hernando, Paulo Nuciforo, Josep M. Miquel, Cristina Molero, Sandra Peiro, Queralt Serra-Camprubi, Guillermo Villacampa, Susana Aguilar, Ana Vivancos, Josep Tabernero, Rodrigo Dienstmann, Teresa Macarulla

Summary: Cholangiocarcinomas are highly heterogeneous at the molecular level. The classification of actionable molecular alterations according to ESCAT is associated with survival in cholangiocarcinoma patients.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

Zhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, Rosa Gallagher, Cristina Saura, Paolo G. Nuciforo, Isabel Calvo, Jay Andersen, Jose Luis Passos-Coelho, Miguel J. Gil-Gil, Begona Bermejo, Debra A. Pratt, Eva M. Ciruelos, Patricia Villagrasa, Matthew J. Wongchenko, Emanuel F. Petricoin, Mafalda Oliveira, Steven J. Isakoff

Summary: This study demonstrates the association between high baseline pAKT levels, mutations in PI3K/AKT pathway components, and the enriched benefit of ipatasertib in TNBC.

CLINICAL CANCER RESEARCH (2022)

Letter Oncology

The Natural History in Lung Neuroendocrine Neoplasms: The Stone Guest Who Matters

Giuseppe Pelosi

JOURNAL OF THORACIC ONCOLOGY (2022)

Article Multidisciplinary Sciences

Lower probability and shorter duration of infections after COVID-19 vaccine correlate with anti-SARS-CoV-2 circulating IgGs

Chiara Ronchini, Sara Gandini, Sebastiano Pasqualato, Luca Mazzarella, Federica Facciotti, Marina Mapelli, Gianmaria Frige', Rita Passerini, Luca Pase, Silvio Capizzi, Fabrizio Mastrilli, Roberto Orecchia, Gioacchino Natoli, Pier Giuseppe Pelicci

Summary: In this study, we found that the probability of infection post-vaccination is significantly lower compared to natural infection, and the duration of infection is shorter. These findings are negatively correlated with circulating antibody levels.

PLOS ONE (2022)

Article Oncology

Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy

Salvatore Pece, Ivana Sestak, Francesca Montani, Micol Tillhon, Patrick Maisonneuve, Stefano Freddi, Kim Chu, Marco Colleoni, Paolo Veronesi, Davide Disalvatore, Giuseppe Viale, Richard Buus, Jack Cuzick, Mitch Dowsett, Pier Paolo Di Fiore

Summary: This study compared two molecular tests for breast cancer patients and found that the StemPrintER Risk Score (SPRS) demonstrated better predictive performance in assessing the risk of distant recurrence. It can help identify high-risk patients and provide guidance for personalized treatment decisions.

EUROPEAN JOURNAL OF CANCER (2022)

Editorial Material Oncology

Labeling Lung Neuroendocrine Neoplasms for Ki-67 Antigen to Score a Bull's-Eye, Not Shoot in the Dark

Giuseppe Pelosi

JOURNAL OF THORACIC ONCOLOGY (2022)

Article Multidisciplinary Sciences

CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer

M. G. Filippone, D. Gaglio, R. Bonfanti, F. A. Tucci, E. Ceccacci, R. Pennisi, M. Bonanomi, G. Jodice, M. Tillhon, F. Montani, G. Bertalot, S. Freddi, M. Vecchi, A. Taglialatela, M. Romanenghi, F. Romeo, N. Bianco, E. Munzone, F. Sanguedolce, G. Vago, G. Viale, P. P. Di Fiore, S. Minucci, L. Alberghina, M. Colleoni, P. Veronesi, D. Tosoni, S. Pece

Summary: The overexpression of CDK12 in breast cancer promotes tumorigenesis and makes the cancer cells vulnerable to therapies targeting folate one-carbon metabolism. CDK12 overexpression is associated with early tumor onset and metastasis and is linked to hyperactivation of the serine-glycine-one-carbon network. CDK12-overexpressing breast tumors show positive response to chemotherapy targeting CDK12-induced metabolic alterations, while being refractory to other types of chemotherapy.

NATURE COMMUNICATIONS (2022)

Article Cell Biology

Aberrant phosphorylation inactivates Numb in breast cancer causing expansion of the stem cell pool

Maria Grazia Filippone, Stefano Freddi, Silvia Zecchini, Silvia Restelli, Ivan Nicola Colaluca, Giovanni Bertalot, Salvatore Pece, Daniela Tosoni, Pier Paolo Di Fiore

Summary: Filippone et al. demonstrate that the frequent activation of PKCs in breast cancer leads to abnormal phosphorylation of the tumor suppressor Numb. Aberrantly phosphorylated Numb affects asymmetric cell division, resulting in expansion of cancer stem cell compartment and aggressive disease course. Asymmetric cell division, controlled by Numb, plays a critical role in preventing uncontrolled expansion of the stem cell compartment. However, in breast cancer, aberrant PKC activation phosphorylates Numb in both progeny, leading to symmetric division and expansion of cancer stem cells.

JOURNAL OF CELL BIOLOGY (2022)

Letter Pathology

MUC6 distribution in the spectrum of pulmonary mucinous adenocarcinoma

Giuseppe Pelosi, Angelica Sonzogni

MODERN PATHOLOGY (2022)

Article Medicine, Research & Experimental

TFEB and TFE3 drive kidney cystogenesis and tumorigenesis

Chiara Di Malta, Angela Zampelli, Letizia Granieri, Claudia Vilardo, Rossella De Cegli, Laura Cinque, Edoardo Nusco, Salvatore Pece, Daniela Tosoni, Francesca Sanguedolce, Nicolina Cristina Sorrentino, Maria J. Merino, Deborah Nielsen, Ramaprasad Srinivasan, Mark W. Ball, Christopher J. Ricketts, Cathy D. Vocke, Martin Lang, Baktiar Karim, Luisa Lanfrancone, Laura S. Schmidt, W. Marston Linehan, Andrea Ballabio

Summary: Birt-Hogg-Dube (BHD) syndrome is a cancer syndrome characterized by the development of various tumors and caused by loss-of-function mutations in the FLCN gene. In this study, the researchers found that TFEB and TFE3, two transcription factors involved in lysosomal biogenesis and autophagy, play a role in renal cystogenesis and tumorigenesis. They also discovered that inhibiting TFEB or TFE3 could prevent tumor formation in BHD renal tumor cell line-derived xenografts. These findings suggest potential therapeutic strategies targeting TFEB and TFE3 for BHD syndrome.

EMBO MOLECULAR MEDICINE (2023)

Article Dermatology

Actionable Genetic Screens Unveil Targeting of AURKA, MEK, and Fatty Acid Metabolism as an Alternative Therapeutic Approach for Advanced Melanoma

Federica Marocchi, Fernando Palluzzi, Paola Nicoli, Marine Melixetian, Giulia Lovati, Giovanni Bertalot, Salvatore Pece, Pier Francesco Ferrucci, Daniela Bossi, Luisa Lanfrancone

Summary: Despite improvements in the management of metastatic melanoma, there are still patients who do not respond to current therapies. Through a preclinical assay, researchers identified a combination therapy targeting AURKA and MAPK/extracellular signal-regulated kinase kinase that was highly effective in metastatic melanoma. Addition of a fatty acid oxidation inhibitor further improved treatment outcomes.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

暂无数据